nuvectis.comCrawled Oct 25, 2026
Ciprocopan (NXP100) is a once-daily oral complement Factor B inhibitor. The page describes its mechanism of action, clinical data, and publications.
Nuvectis Pharma (Nasdaq: NVCT) clinical trials of NXP900 in advanced cancers, including studies with lorlatinib in ALK+ lung cancer and osimertinib in NSCLC.
NXP200 is an oral BRAF inhibitor targeting Class I, II, and III mutations. The page covers its mechanism of action and clinical data.
NXP900 inhibits SRC and YES1 functions. The page details its mechanism of action, clinical data, and publications.
Nuvectis Pharma (Nasdaq: NVCT) scientific publications and posters on its NXP100, NXP200 and NXP900 programs, grouped by program and available as PDFs.
Nuvectis Pharma (Nasdaq: NVCT) investor events, conference presentations and webcasts, with the latest corporate presentation available to download as a PDF.
Nuvectis Pharma (Nasdaq: NVCT) investor relations: NVCT stock quote, latest press releases, events, the corporate presentation and SEC filings.
Press releases from Nuvectis Pharma (Nasdaq: NVCT), a clinical-stage biopharmaceutical company focused on complement-related diseases and oncology.
Contact Nuvectis Pharma (Nasdaq: NVCT) investor relations and media. Company contact: Ron Bentsur, Chairman, CEO and President, in Fort Lee, New Jersey.
Nuvectis Pharma develops therapies for immune complement-related conditions and oncology, including ciprocopan, NXP200, and NXP900.
Nuvectis Pharma outlines its privacy policy, detailing what information the website collects, how it is used, and how it is protected.
Legal disclaimer for the Nuvectis Pharma (Nasdaq: NVCT) website, covering copyright, currency of information and the note on forward-looking statements.
Terms and conditions of use for the Nuvectis Pharma, Inc. (Nasdaq: NVCT) website, covering acceptance of terms, use of information and limits of liability.